Retosiban(Retosiban) - 药物靶点：OXTR_专利_临床

概要

基本信息

药物类型

小分子化药

别名

Retosiban (USAN)、GSK-221149、GSK-221149A

靶点

OXTR

作用方式

拮抗剂

作用机制

OXTR拮抗剂(催产素受体拮抗剂)

治疗领域

泌尿生殖系统疾病

在研适应症-

非在研适应症

早产早泄

原研机构

GSK Plc

在研机构-

非在研机构

GSK Plc

权益机构-

最高研发阶段终止临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

结构/序列

分子式C27H34N4O5

InChIKeyPLVGDGRBPMVYPB-FDUHJNRSSA-N

CAS号820957-38-8

关联

11

项与 Retosiban 相关的临床试验

NCT02377466

/ Terminated临床3期

Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Placebo for Women in Spontaneous Preterm Labor

The study's primary objective is to demonstrate the superiority of retosiban to prolong pregnancy and improve neonatal outcomes compared with placebo. It is a Phase III, randomized, double-blind, parallel-group, multicenter study and will be conducted in approximately 900 females, aged 12 to 45 years, with an uncomplicated, singleton pregnancy and intact membranes in preterm labor between 24^0/7 and 33^6/7 weeks of gestation. Eligible maternal subjects will be randomly assigned in a 1:1 ratio to receive either retosiban IV infusion or placebo IV infusion over 48 hours. If not previously administered, antenatal corticosteroid treatment should be administered as either (1) two 12-mg doses of betamethasone given intramuscularly 24 hours apart or (2) four 6-mg doses of betamethasone administered intramuscularly every 12 hours. A single rescue course of antenatal corticosteroids is permitted if the antecedent treatment was at least 7 days prior to study enrolment. Investigators have discretion to use a standardized regimen of magnesium sulphate, as well as intrapartum antibiotic prophylaxis for perinatal group B streptococcal infection. Prior to randomization, each subject will be stratified by progesterone treatment and gestational age. The progesterone strata will consist of subjects on established progesterone therapy or subjects not on established progesterone therapy at Screening. The study will comprise 6 phases: Screening, Inpatient Randomized Treatment, Post Infusion Assessment, Delivery, Maternal Post-Delivery Assessment, and Neonatal Medical Review. The duration of any subject's (maternal or neonatal) participation in the study will be variable and dependent on gestational ages (GA) at study entry and the date of delivery.

开始日期2016-02-29

申办/合作机构

GSK Plc

[+1]

NCT02292784

/ Completed临床3期

Follow-Up Study to Assess Long-Term Safety and Outcomes in Infants and Children Born to Mothers Participating in Retosiban Treatment Studies

The primary objective of this study is to assess the safety and outcomes of infants and children who were exposed to retosiban or comparator in utero in the Phase III spontaneous preterm labor (SPTL) treatment studies, to provide assurance that treatment is not associated with significant adverse outcomes in early childhood. The enrolled infants and children will be followed at pre-specified intervals until they reach 24 months chronological age. This study does not require medical interventions or study visits to an investigational site, instead, parents or legal guardians will be prompted at certain time points to complete developmental questionnaires and other data on their children's health status via an electronic device. Data collected during the infant and child follow up study will be managed by a centralized research coordinating center (RCC). Regionally based pediatricians will serve as study principal investigators (referred to as RCC-PIs) for this study. All communications the RCC-PI has with the parent/legal guardian or the child's health care provider (HCP) will occur remotely; there will be no clinic visits.

开始日期2015-06-01

申办/合作机构

GSK Plc

[+1]

NCT02292771

/ Terminated临床3期

Randomized, Double-blind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban Therapy for Women in Spontaneous Preterm Labor

The primary objective of this study is to demonstrate the superiority of retosiban to prolong pregnancy in females with spontaneous preterm labor compared with atosiban. This objective is based on the hypothesis that prolonging the time to delivery in the absence of harm may benefit the newborn, particularly in women who experience spontaneous preterm labor at early gestational ages (GA). This study is designed to test this hypothesis through a direct comparison with atosiban, a mixed oxytocin vasopressin antagonist indicated for short-term use to delay imminent preterm birth in women between 24^0/7 and 33^6/7 weeks' gestation in preterm labor. This is a randomized, double-blind, double-dummy study, which consists of 6 phases: Screening, Inpatient Randomized Treatment, Post Infusion Assessment, Delivery, Maternal Post Delivery Assessment, and Neonatal Medical Review. Approximately 330 females will be randomly assigned to retosiban or atosiban treatment in a 1:1 ratio. The duration of any one subject's (maternal or neonatal) participation in the study will be variable and dependent on GA at study entry and the date of delivery.

开始日期2015-03-16

申办/合作机构

GSK Plc

[+1]

100 项与 Retosiban 相关的临床结果

登录后查看更多信息

100 项与 Retosiban 相关的转化医学

登录后查看更多信息

100 项与 Retosiban 相关的专利（医药）

登录后查看更多信息

28

项与 Retosiban 相关的文献（医药）

2023-07-01·American journal of perinatology4区 · 医学

Safety and Outcomes in Infants Born to Mothers Participating in Retosiban Treatment Trials: ARIOS Follow-up Study

4区 · 医学

Article

作者: Pimenta, Jeanne M. ; Beach, Kathleen J. ; Saade, George R. ; Correa, Erika Ochoa ; Powell, Marcy ; Scott, Rhona ; Thornton, Steve ; Haque, Nazneen ; Snidow, Jerry ; Miller, Diane

Objective Retosiban, an oxytocin receptor antagonist, was developed for treating spontaneous preterm labor (sPTL) in women with intact membranes. This ARIOS follow-up study aimed to characterize clinical safety, morbidity, and mortality of infants exposed to retosiban or comparator over 2 years. Study Design ARIOS prospectively assessed outcomes in infants whose mothers received at least one dose of retosiban or comparator (placebo/atosiban) in two Phase 3 sPTL trials. Both trials were terminated prematurely owing to poor enrolment. Infants could be enrolled into ARIOS from 28 days after estimated due date until hospital discharge or up to 9 months (corrected age). An internally developed questionnaire detailing medical conditions, mortality and resource use (Child Health Inventory; CHI), Ages and Stages Questionnaire-3 (ASQ-3), Modified Checklist for Autism in Toddlers–Revised with Follow-Up, and Child Behavior Checklist for Ages 1.5 to 5 were completed remotely by parents or legal guardians at prespecified intervals. Serious adverse events (SAEs) were primarily captured via CHI. No comparative statistical analysis was conducted between treatment arms. Results A total of 49 (86%) infants who had received retosiban and 49 (78%) infants who had received a comparator were enrolled in ARIOS. No deaths occurred during the study. Nine infants experienced SAEs: 6/49 (12.2%) infants in the comparators group and 3/49 (6.1%) in the retosiban group. Of the nine SAEs, seven were due to infections, three, and four in the retosiban and comparators groups, respectively. Based on ASQ-3 score, the incidence of neurodevelopmental delay at 18 and 24 months were 0/18 (0%) and 2/25 (8%) with retosiban and 7/22 (31.8%) and 3/21 (14.3%) with comparator, respectively. Conclusion The current study showed no unexpected adverse outcome or impairment with retosiban based on safety monitoring and neurodevelopment assessments. No further follow-up is intended owing to the discontinuation of clinical development of retosiban. Key Points

2021-09-02·Current medical research and opinion4区 · 医学

Novel oxytocin receptor antagonists for tocolysis: a systematic review and meta-analysis of the available data on the efficacy, safety, and tolerability of retosiban

4区 · 医学

Review

作者: Ulibarri, Hollie ; Cieminski, Kaitlynne ; Ware, Kelly ; Marchand, Greg ; King, Alexa ; Blumrick, Richard ; Ruuska, Alexandra D. ; Masoud, Ahmed Taher ; Calteux, Nicolas ; Ruther, Stacy ; Sainz, Katelyn ; Brazil, Giovanna

OBJECTIVE:

To assess the efficacy, safety, and tolerability of retosiban-a novel tocolytic unavailable in the US-in the management of preterm labor.

METHODS:

We searched ClinicalTrials.Gov, MEDLINE, PubMed, SCOPUS, Web of Science, and the Cochrane Library for relevant clinical trials using the terms "retosiban" and "preterm labor" through 09/2020. We included all published randomized clinical trials (three) that compared retosiban to placebo for preterm labor, excluding conferences, books, reviews, posters, case reports, and animal studies. We analyzed homogeneous data under the fixed-effects model and heterogeneous data under the random-effects model.

RESULTS:

We included all randomized clinical trials addressing this topic, which ultimately resulted in three trials with a total of 116 patients. There were no significant differences between retosiban and placebo in births at term (RR = 0.41, p = .02), births ≤7 days from the first study treatment (RR = 0.59, p = .23), or administration of rescue tocolytic (RR = 0.36, p = .07); the maternal adverse events of headache, anemia, constipation, or urinary tract infection (p > .05); or neonatal outcomes of Apgar score at 1 min (p = .88) or 5 min (p = .69), weight (p = .23), head circumference (p = .55), malnutrition (p = .27), hyperbilirubinemia (RR = 0.56, p = .21), jaundice (RR = 1.21, p = .84), respiratory distress (RR = 0.53, p = .49), or tachypnea (RR = 0.40, p = .42).

CONCLUSION:

With the limited high quality evidence available, retosiban demonstrates no clear benefit over placebo in the management of preterm labor. Nevertheless, its favorable safety profile, oral bioavailability, and novel mechanism of action and the limited number of studies available for review warrant further analysis.

2021-08-01·American journal of perinatology4区 · 医学

Erratum: Randomized Trials of Retosiban versus Placebo or Atosiban in Spontaneous Preterm Labor

4区 · 医学

Article

作者: Powell, Marcy ; Saade, George ; Shennan, Andrew ; Beach, Kathleen J. ; Parilla, Barbara V. ; Komatsu, Yosuke ; Thornton, Steven ; Liu, Feng ; McKain, Laura ; Hadar, Eran ; Snidow, Jerry ; Montague, Timothy H.

100 项与 Retosiban 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D08986	Retosiban	-	DB11818

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
早产	临床3期	美国	GSK Plc	2015-03-16
早产	临床3期	比利时	GSK Plc	2015-03-16
早产	临床3期	德国	GSK Plc	2015-03-16
早产	临床3期	以色列	GSK Plc	2015-03-16
早产	临床3期	意大利	GSK Plc	2015-03-16
早产	临床3期	墨西哥	GSK Plc	2015-03-16
早产	临床3期	西班牙	GSK Plc	2015-03-16
早产	临床3期	瑞典	GSK Plc	2015-03-16
早产	临床3期	英国	GSK Plc	2015-03-16
早泄	临床1期	美国	GSK Plc	2007-03-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT02292784 (ARIOS, Pubmed \| Am J Perinatol)	临床3期	-	-	Comparator (Placebo/Atosiban)	選蓋簾襯範窪鬱糧齋觸(遞廠淵獵窪範衊積構鏇) = 獵願鹽壓夢糧鬱餘觸淵簾蓋廠艱觸遞餘廠鹹憲 (積艱醖鹹淵憲醖遞窪壓 )	-	2021-08-05
NCT02292784 (ARIOS, CTgov)	临床3期	早产	98	Placebo (Placebo (200719 Study))	築蓋膚積齋夢構襯網構 = 糧鑰積憲簾鏇齋襯鹹築鏇憲憲蓋襯淵遞壓艱簾 (顧窪選構範簾鏇壓範範, 願窪艱積廠簾憲願鹹構 ~ 齋壓鏇齋衊窪窪襯鹹鑰) 更多	-	2020-07-09
				Atosiban (Atosiban (200721 Study))	築蓋膚積齋夢構襯網構 = 壓襯鹹膚壓廠膚鬱衊壓鏇憲憲蓋襯淵遞壓艱簾 (顧窪選構範簾鏇壓範範, 製壓遞築製襯蓋淵範糧 ~ 鏇淵衊網蓋鑰蓋醖衊艱) 更多
NCT02292771 (CTgov)	临床3期	早产	97	Retosiban (Retosiban)	製餘範選鏇鏇餘淵顧艱(鹽範觸範餘鏇築鹹積積) = 觸壓簾簾構願淵範蓋製製簾壓選壓鹽襯憲襯鏇 (齋鏇鏇鏇鹽夢艱憲膚顧, 2.990) 更多	-	2018-09-10
				Atosiban (Atosiban)	製餘範選鏇鏇餘淵顧艱(鹽範觸範餘鏇築鹹積積) = 鹹網築構範觸鑰鑰簾鹽製簾壓選壓鹽襯憲襯鏇 (齋鏇鏇鏇鹽夢艱憲膚顧, 2.531) 更多
NCT02377466 (NEWBORN-1, CTgov)	临床3期	早产	25	Placebo IV infusion (Placebo)	獵夢憲鹽膚醖簾憲鹽願(顧網網齋壓淵願願齋選) = 鑰醖衊構廠憲構繭餘鹽夢鹽鹽遞鬱積壓蓋齋壓 (簾壓獵壓衊鏇構膚鏇鏇, 14.987) 更多	-	2018-07-19
				Retosiban IV infusion (Retosiban)	獵夢憲鹽膚醖簾憲鹽願(顧網網齋壓淵願願齋選) = 觸鏇齋鬱壓艱願築觸遞夢鹽鹽遞鬱積壓蓋齋壓 (簾壓獵壓衊鏇構膚鏇鏇, 22.993) 更多
NCT00404768 (Pubmed \| Br J Clin Pharmacol) 人工标引	临床2期	早产	64	retosiban	築簾襯遞簾製廠遞製淵(鬱鏇衊憲襯構壓憲簾衊) = 鹹願繭鏇繭願鹹糧構鑰顧遞鏇鏇繭獵願選鏇艱 (襯醖夢蓋構積積網糧鹽 ) 更多	积极	2015-10-01
				Placebo	築簾襯遞簾製廠遞製淵(鬱鏇衊憲襯構壓憲簾衊) = 鏇壓鹹築選構選夢鏇構顧遞鏇鏇繭獵願選鏇艱 (襯醖夢蓋構積積網糧鹽 ) 更多
NCT01702376 (Pubmed \| Clin Ther)	临床1期	-	52	Retosiban 100 mg	艱鑰顧壓衊觸鑰鹹顧膚(糧繭遞鏇鏇簾觸製繭鏇) = 夢醖壓窪選築齋夢積遞窪夢網製鹽糧夢網醖鬱 (選齋鏇築範壓觸醖鏇襯 )	-	2015-07-01
				Retosiban 800 mg	艱鑰顧壓衊觸鑰鹹顧膚(糧繭遞鏇鏇簾觸製繭鏇) = 鹹窪壓憲醖觸窪蓋廠鬱窪夢網製鹽糧夢網醖鬱 (選齋鏇築範壓觸醖鏇襯 )